Cargando…

1459. Oral Cephalosporins vs. Fluoroquinolones for the Empiric Treatment of Acute Uncomplicated Pyelonephritis

BACKGROUND: The Infectious Diseases Society of America guidelines for the treatment of acute uncomplicated pyelonephritis (AUP) recommend oral fluoroquinolones (FQs) as a first-line agent in patients not requiring hospitalization. However, with increasing rates of FQ and trimethoprim/sulfamethoxazol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Kevin, Ortwine, Jessica, Mang, Norman, Wei, Wenjing, Prokesch, Bonnie C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809916/ http://dx.doi.org/10.1093/ofid/ofz360.1323

Ejemplares similares

A retrospective review of oral cephalosporins versus fluoroquinolones for the treatment of pyelonephritis
por: Lin, Kevin, et al.
Publicado: (2022)

1842. Fluoroquinolone Usage Reduction in the Outpatient Setting
por: Mang, Norman, et al.
Publicado: (2018)

2077. Fluoroquinolone Usage Reduction in the Outpatient Setting
por: Lin, Kevin, et al.
Publicado: (2019)

1491. Standard- vs. High-dose Trimethoprim-Sulfamethoxazole for Stenotrophomonas maltophilia pneumonia
por: Hall, Brenton C, et al.
Publicado: (2020)

Cost-Savings Associated With Delayed Switch To Outpatient Antibiotic Regimen For Patients Requiring Daptomycin Therapy
por: Wei, Wenjing, et al.
Publicado: (2017)

218. IV to PO Conversion of Antimicrobials: Small Intervention, Big Impact
por: Wei, Wenjing, et al.
Publicado: (2018)

Decreased Outpatient Fluoroquinolone Prescribing Using a Multimodal Antimicrobial Stewardship Initiative
por: Lin, Kevin, et al.
Publicado: (2020)

2177. Institutional Prevalence of Drug-Resistant Pathogens in Community-Acquired Pneumonia
por: Ding, Helen, et al.
Publicado: (2022)

1061. Decreased Utilization of Piperacillin–Tazobactam for Escherichia coli and Klebsiella Bacteremia due to Selective Susceptibility Reporting
por: Zahlanie, Yorgo, et al.
Publicado: (2019)

Impact of Education on Fluoroquinolone Use in Uncomplicated Cystitis
por: Ferren, Ryan, et al.
Publicado: (2017)

1454. Cephalosporins and Quinolones Account for 95 Percent of Oral Antibiotic Treatment for Uncomplicated Cystitis in Japan
por: Kusama, Yoshiki, et al.
Publicado: (2019)

1115. Use of a Fluoroquinolone (FQ) vs. a Non-Fluoroquinolone (Non-FQ)-Based Antibiotic Regimen in the Treatment of Acute, Uncomplicated Diverticulitis
por: Mourani, Jessyca, et al.
Publicado: (2018)

1459 Adjunctive Corticosteroid Therapy in the Treatment of Coccidioidal Meningitis
por: Thompson, George, et al.
Publicado: (2014)

Comparison of Second- and Third-Generation Cephalosporin as Initial Therapy for Women with Community-Onset Uncomplicated Acute Pyelonephritis
por: Chang, U-Im, et al.
Publicado: (2015)

108. Evaluation of the Impact of Dalbavancin Usage on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital
por: Wei, Wenjing, et al.
Publicado: (2021)

1822. Clinical Outcomes Associated with Oral Beta-Lactam Therapy versus Oral Fluoroquinolones/TMP-SMX for Uncomplicated Gram-Negative Bacteremia
por: Kaur, Satwinder S, et al.
Publicado: (2022)

1347. Improved Antibiotic Prescribing Practices for Respiratory Infections Through Use of Computerized Order Sets and Educational Sessions in Pediatric Clinics
por: Zahlanie, Yorgo, et al.
Publicado: (2020)

277. Comparison of Oral Beta-Lactams and Fluoroquinolones for Step-Down in Uncomplicated Enterobacterales Blood Stream Infections
por: Ngo, Nichol, et al.
Publicado: (2020)

Minimal impact of selective susceptibility reporting on the use of piperacillin-tazobactam for Escherichia coli and Klebsiella bacteremia
por: Zahlanie, Yorgo, et al.
Publicado: (2021)

1459. Association of Antibiotic Prophylaxis Duration and Length of Stay in Patients Undergoing Coronary Artery Bypass Graft Procedure
por: Alnaimi, Shaikha, et al.
Publicado: (2023)

1936. Implementation of IV Push Antibiotics for OPAT in a Safety Net Hospital Following a National Fluid Shortage
por: Bhavan, Kavita, et al.
Publicado: (2018)

427. Trends in Hospital-onset Escherichia coli Infections Resistant to Fluoroquinolones and Extended-spectrum Cephalosporins, 2012-2020
por: Hood, Nicole, et al.
Publicado: (2022)

1072. Streamlining to Oral β-Lactam vs. Fluoroquinolone as Definitive Therapy for Enterobacteriaceae Bacteremia
por: Fong, Karen, et al.
Publicado: (2018)

2685. Oral Third-Generation Cephalosporins vs. Levofloxacin for Antibacterial Prophylaxis in Neutropenic Patients with Hematologic Malignancies
por: DeVoe, Catherine, et al.
Publicado: (2019)

1043 Fluoroquinolone Resistance in Community-acquired Acute Pyelonephritis: Clinical Characteristics, Risk Factors and Clinical Response according to Fluoroquinolone MIC of Uropathogens
por: Kim, Yeonjae, et al.
Publicado: (2014)

70. Impact of Fluoroquinolone Susceptibility Suppression on Discharge Prescribing for Acute Uncomplicated Cystitis
por: Hayden, Dillon, et al.
Publicado: (2020)

1459. The Scope of Mycoplasma Pneumoniae Pneumonia Diagnosed by Multiplex Polymerase Chain Reaction Respiratory Viral Panel in Pediatric Patients in Hawaii
por: Porter, Mark, et al.
Publicado: (2018)

1459. Prevalence of Enterovirus and Parechovirus in Children with Acute Gastroenteritis and in Healthy Controls over a 7-year Period; 2011-2018
por: Sasidharan, Anjana, et al.
Publicado: (2022)

Comparison of antimicrobial resistance in patients with obstructive pyelonephritis associated with ureteral stones and uncomplicated pyelonephritis
por: Jang, Young Rock, et al.
Publicado: (2022)

165. Comparative Effectiveness of Oral Fluoroquinolones vs. β-Lactams for the Treatment of Patients with Enterobacteriaceae Bloodstream Infections
por: Bjork, Lauren, et al.
Publicado: (2019)

2184. Effect of Adjusted CLSI Breakpoints on Center-wide Fluoroquinolone Susceptibilities for Enterobacteriaceae and Pseudomonas aeruginosa: Is It Time to Restrict Empiric Fluoroquinolone Use?
por: Sansom, Sarah, et al.
Publicado: (2019)

Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital
por: Lueking, Richard, et al.
Publicado: (2022)

1180. Empiric treatment of uncomplicated intraabdominal infection with cefazolin with or without metronidazole
por: Borkowski, Jaime, et al.
Publicado: (2023)

Empiric antibiotic therapy in acute uncomplicated urinary tract infections and fluoroquinolone resistance: a prospective observational study
por: Aypak, Cenk, et al.
Publicado: (2009)

Long-term impact of fluoroquinolone-sparing strategies for empirical treatment of acute uncomplicated cystitis among ambulatory patients
por: Kon, Shelley, et al.
Publicado: (2022)

Correction to Lancet Glob Health 2020; 8: e1459–60
Publicado: (2020)

Fluoroquinolones Protective against Cephalosporin Resistance in Gram-negative Nosocomial Pathogens
por: Schwaber, Mitchell J., et al.
Publicado: (2004)

1042 Prevalence of Fluoroquinolone- and Ceftriaxone-resistant E. coli among U.S. Emergency Department Patients with Acute Pyelonephritis
por: Moran, Gregory, et al.
Publicado: (2014)

2094. Acceptability of Antibiotic Substitutions for Fluoroquinolones and Third and Fourth-generation Cephalosporins: A Report from the VA-CDC Practice-Based Research Network (PBRN)
por: Goetz, Matthew B, et al.
Publicado: (2019)

1044. Aztreonam (AZT) vs. Cephalosporin (CEP) Therapy for the Treatment of Gram-Negative Bacteremia
por: Shah, Sunish, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dpoe0u0csmn55som7bdbj30vv4